Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysis.
To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [<or=$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy >or=30%, and a $100 vaccine at vaccine efficacy >or=70%. High MRSA prevalence (>or=25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.
Lee
Bruce Y
BY
Section of Decision Sciences and Clinical Systems Modeling, University of Pittsburgh, Pittsburgh, PA, USA. BYL1@pitt.edu <BYL1@pitt.edu>
Wiringa
Ann E
AE
Bailey
Rachel R
RR
Lewis
G Jonathan
GJ
Feura
Jared
J
Muder
Robert R
RR
D003362:Cost-Benefit Analysis; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000276:immunology*; D015233:Models, Statistical; D009985:Orthopedics; D011300:Preoperative Care / Q000191:economics* / Q000379:methods*; D013203:Staphylococcal Infections / Q000191:economics / Q000517:prevention & control*; D013209:Staphylococcal Vaccines / Q000191:economics* / Q000276:immunology*; D013530:Surgical Wound Infection / Q000191:economics / Q000517:prevention & control*
D013209:Staphylococcal Vaccines